182921-01-3

Upstream product

• 51-67-2 tyrosamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 64318-28-1 N-t-butoxycarbonyl-tyramine 
• 100-39-0 benzyl bromide 

Downstream Products

• 788824-89-5 N-t-butoxycarbonyl-N-butyl-O-benzyltyramine 
• 788824-85-1 N-t-butoxycarbonyl-N-methyl-O-benzyltyramine 
• 788824-87-3 N-t-butoxycarbonyl-N-ethyl-O-benzyltyramine 
• 182921-02-4 N-t-butoxycarbonyl-N-allyl-2-[(4-benzyloxy)-phenyl]-ethylamine 
• 64318-28-1 N-t-butoxycarbonyl-tyramine 
• 1415684-17-1 (2S,3R,3aS,12bR)-1,2,3,3a,4,5,7,8-octahydro-11-benzyloxy-2-methyl-5-oxo-cyclopenta[2,3]pyrrolo[2,1-a]isoquinoline-3-carboxylic acid 
• 1415684-16-0 (2S,3R,3aS,12bR)-1,2,3,3a,4,5,7,8-octahydro-11-benzyloxy-2-methyl-3-nitromethyl-5-oxo-cyclopenta[2,3]pyrrolo[2,1-a]isoquinoline 
• 1268607-25-5 [2-(4-benzyloxyphenyl)-ethyl]-pteridin-4-yl-amine 
• 51179-05-6 2-(4-(benzyloxy)phenyl)ethanamine 
• 24958-41-6 N-methyl-O-benzyltyramine hydochloride 
• 32293-43-9 N,O-dibenzyltyramine hydrochloride 
• 788824-88-4 N-t-butoxycarbonyl-N-propyl-O-benzyltyramine 
• 788824-90-8 N-t-butoxycarbonyl-N-benzyl-O-benzyltyramine 

Relevant academic research and scientific papers

Guanidinium compounds with sub-micromolar activities against Mycobacterium tuberculosis. Synthesis, characterization and biological evaluations

Seven polycharged species, incorporating 1, 2, 3, 4 and 6 guanidine arms organized around a benzene core were synthesized and assayed as anti-mycobacterial agents against Mycobacterium tuberculosis. They display MIC values comprised between 25 and 12.5 μM (close to ethambutol EMB) for the mono- and the hexa-substituted derivatives, and 0.8 μM (close to isoniazid and streptomycin) for the tri-substituted derivative. The three bi- and the tetra-substituted analogs displayed MIC values of ca. 6.5-3.0 μM. The latter were also evaluated against the isoniazid-resistant MYC5165 strain, resulting in highly interesting micromolar or sub-micromolar MIC, ca. 4-125 times more active than isoniazid. These preliminary results are attractive for the development of new anti-TB agents.

Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity

Since overactivation of NMDA receptors is associated with neurodegenerative disorders, the design and development of subunit-selective NMDA receptor antagonists are of great interest. In order to avoid the formation of quinone-like intermediates as starti

Diverse alkaloid-like structures from a common building block

A wealth of unique enantiopure polycyclic alkaloid-like scaffolds can be prepared on a multigram scale in only a few steps from a common, commercially available intermediate. The attached nitromethyl group can then be used to construct highly diverse func

SYNTHESIS OF POLYCYCLIC ALKALOIDS

Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused

PTERIDINES AND THEIR USE AS AGROCHEMICALS

The present disclosure relates to 1- or 2-(4-(aryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and 1- or 2-(4-(heteroaryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and their use as agrochemicals and animal health products.

PTERIDINES AND THEIR USE AS AGROCHEMICALS

The present disclosure relates to 1- or 2-(4-(aryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and 1- or 2-(4-(heteroaryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and their use as agrochemicals and animal health products.

NOVEL CHROMEN-2-ONE BASED HYDROXAMIC ACID DERIVATIVES HAVING ANTI-INFLAMMATORY ACTIVITY, THE PREPARATION THEREOF AND A COMPOSITION CONTAINING THE SAME FOR TREATING INFLAMMATORY DISEASE

The present invention relates to novel chromen-2-one based hydroxamic acid derivatives having anti-inflammatory activity, the preparation thereof and a composition containing the same for treating inflammatory disease.

Trace amine-associated receptor agonists: Synthesis and evaluation of thyronamines and related analogues

We have previously shown that several thyronamines, decarboxylated and deiodinated metabolites of the thyroid hormone, potently activate an orphan G protein-coupled receptor in vitro (TAAR1) and induced hypothermia in vivo on a rapid time scale [Scanlan, T. S.; Suchland, K. L.; Hart, M. E.; Chiellini, G.; Huang, Y.; Kruzich, P. J.; Frascarelli, S.; Crossley, D. A.; Bunzow, J. R.; Ronca-Testoni, S.; Lin, E. T.; Hatton, D.; Zucchi, R.; Grandy, D. K. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med. 2004, 10 (6), 638-642]. Herein, we report the synthesis of these thyronamines. Additionally, a large number of thyroamine derivatives were synthesized in an effort to understand the molecular basis of TAAR1 activation and hypothermia induction. Several derivatives were found to potently activate both rTAAR1 and mTAAR1 in vitro (compounds 77, 85, 91, and 92). When administered to mice at a 50 mg/kg dose, these derivatives all induced significant hypothermia within 60 min and exhibited a hypothermic induction profile analogous to 3-iodothyronamine (1, T1AM) except 91, which proved to be more efficacious. On the basis of this result, a dose-dependent profile for 91 was generated and an ED50 of 30 μmol/kg was calculated. Compound 91 proved to be more potent than T1AM for TAAR1 activation and exhibits increased potency and efficacy for hypothermia induction. These data further strengthen the pharmacological correlation linking TAAR1 activation by thyronamines and hypothermia induction in mice.